Search clinical trials for: Zanubrutinib

Total 169 results

1
2
3
4
›

Sun Yat-sen University

Recruiting

Zanubrutinib-based Induction and Maintenance Therapy in Young and Fit Patients With Untreated Mantle Cell Lymphoma

Mantle Cell Lymphoma

China
Institute of Hematology & Blood Diseases Hospital...

Recruiting

Safety and Efficacy of Zanubrutinib in the Treatment of Antiphospholipid Syndrome With Secondary Thrombocytopenia

Thrombocytopenia | Antiphospholipid Syndrome | Treatment

China
Fudan University

Recruiting

ZR-CHOP in DLBCL With Specific Gene Abnormality

Diffuse Large B Cell Lymphoma

China
Henan Cancer Hospital

Not yet recruiting

This is a Phase II, Open-label, Multicentre Study of Zanubrutinib-containing Regimens in Patients With Newly Diagnosed Mantle Cell Lymphoma

Lymphoma, Non-Hodgkin | Lymphoma, Mantle-Cell
Xuanwu Hospital, Beijing

Recruiting

An Open Label Study of the Effects and Safety of Zanubrutinib in NMOSDs Adult Patients

Neuromyelitis Optica

China
The First Affiliated Hospital of Xiamen University
Sun Yat-sen University; Fujian Cancer Hospital; Huazhong University of Science... and other collaborators

Recruiting

Zanubrutinib in Combination With Obinutuzumab (ZO) for Newly Diagnosed Follicular Lymphoma

Follicular Lymphoma | Newly Diagnosed

China
The First Affiliated Hospital of Soochow University

Recruiting

Zanubrutinib-rituximab(ZR) in Patients With Newly Diagnosed Untreated Mantle Cell Lymphoma

Untreated Mantle Cell Lymphoma

China
French Innovative Leukemia Organisation
BeiGene

Not yet recruiting

Study Evaluating the Efficacy and Tolerance of a Zanubrutinib and BGB-11417 Combination in Patients Previously Treated for Waldenström Macroglobulinemia (WAZABI)

Waldenstrom Macroglobulinemia

France
Institute of Hematology & Blood Diseases Hospital...

Recruiting

A Prospective, One-arm and Open Clinical Study of Zanubrutinib in the Treatment of Immune Thrombocytopenia

Immune Thrombocytopenia | Treatment

China
Matthew C. Baker
Stanford University

Active, not recruiting

Zanubrutinib in Patients with IgG4-Related Disease

IgG4 Related Disease

United States
Huazhong University of Science and Technology

Recruiting

Zanubrutinib Combined With R-CHOP in the Treatment of Newly Diagnosed DLBCL With p53 Protein Expression

Diffuse Large B Cell Lymphoma

China
Fudan University

Recruiting

A Multicenter, Prospective, Phase II Study of Zanubrutinib for Maintenance in Patients With Mantle Cell Lymphoma

Mantle Cell Lymphoma | Maintenance Therapy

China
Henan Cancer Hospital

Recruiting

Rituximab,Zanubrutinib in Combination With Lenalidomide, Followed by Zanubrutinib or Lenalidomide Maintenance in Patients With Primary or Secondary CNS Lymphoma

Central Nervous System Lymphoma

China
Stichting Hemato-Oncologie voor Volwassenen Nederland

Recruiting

Zanubrutinib in Primary Cold Agglutinin Disease (HOVON169CAD)

Lymphoma

Denmark, Norway, Belgium, Netherlands
Navy General Hospital, Beijing

Not yet recruiting

Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL

Diffuse Large B-cell Lymphoma

China
PETHEMA Foundation

Recruiting

Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

Spain
Ruijin Hospital

Not yet recruiting

Zanubrutinib Combined With BEAM for ASCT in Relapsed and Refractory DLBCL

DLBCL
Fondazione Italiana Linfomi - ETS

Not yet recruiting

Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients (FIL_MOZART)

Follicular Lymphoma

Italy
University Health Network, Toronto

Not yet recruiting

A Study to Evaluate Zanubrutinib and Tislelizumab in Progressive Lymphoma Post CAR-T (ZeTA)

Large B-cell Lymphoma
UMC Utrecht
BeiGene

Recruiting

Zanubrutinib Treatment in Patients With IgM Monoclonal Gammopathy and Antri-MAG Related Polyneuropathy (MAGNAZ)

Monoclonal Gammopathy of Uncertain Significance

Netherlands
Fudan University
Xiangya Hospital of Central South University; Shanghai Changzheng Hospital; Baotou...

Active, not recruiting

A Study to Evaluate Efficacy and Safety of Zanubrutinib With R-CHOP in Newly Diagnosed Non-GCB DLBCL Patients With Double Expression

Diffuse Large B-cell Lymphoma(DLBCL)

China
Shanxi Province Cancer Hospital

Not yet recruiting

A Single-arm, Single-center, Open-label Phase II Study of Zanubrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle CellLymphoma Patients (Z+RCHOP/RDHAP)

Mantle Cell Lymphoma

China
Ruijin Hospital

Recruiting

Immunobridging/Maintenance Therapy Versus Non-bridging Therapy in CAR-T Therapy for Low-risk R/R B-NHL (CART R/R NHL)

CART Therapy | B-NHL

China
Sun Yat-sen University

Active, not recruiting

Zanubrutinib and Rituximab Followed by R-DHAOx Then Maintenance with Zanubrutinib for Newly-Diagnosed MCL

Mantle Cell Lymphoma | Newly-diagnosed Mantle Cell Lymphoma

China
VA Office of Research and Development

Not yet recruiting

A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (Benefit VA)

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Ruijin Hospital

Recruiting

The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma

Diffuse Large B-Cell Lymphoma

China
Sun Yat-sen University

Not yet recruiting

High-dose Methotrexate Combined with Thiotepa and Zanubrutinib in the Treatment of Newly Diagnosed PCNSL (MTZ)

Primary Central Nervous System Lymphoma (PCNSL) | Non Hodgkin Lymphoma (NHL)

China
Institute of Hematology & Blood Diseases Hospital

Not yet recruiting

Zanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLL (ZFCR/ZBR)

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | Newly Diagnosed

China
The Lymphoma Academic Research Organisation
Hoffmann-La Roche; BeiGene

Recruiting

A Phase II Study Evaluating Glofitamab in Combination With Venetoclax Plus Zanubrutinib or Venetoclax Alone in Subjects With Untreated or Relapsed/Refractory High-risk Mantle-cell Lymphoma (GLOASIS)

Lymphoma, Mantle-Cell

France, Belgium
Peng Liu

Recruiting

Prospective Clinical Study of ZPR Regimen in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Diffuse Large B Cell Lymphoma

China
Weill Medical College of Cornell University
Genentech, Inc.; BeiGene

Recruiting

Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab

Leukemia, Lymphocytic, Chronic, B-Cell

United States
Peng Liu

Recruiting

Prospective Clinical Study of ZPR Regimen in Elderly Treatment-naive Diffuse Large B-cell Lymphoma

Diffuse Large B Cell Lymphoma

China
Institute of Hematology & Blood Diseases Hospital...

Recruiting

The Safety and Efficacy of Zanubrutinib in Refractory/Relapsed Autoimmune Hemolytic Anemia

Refractory/Relapsed Autoimmune Hemolytic Anemia

China
Peking University People's Hospital

Completed

A Study of Zanubrutinib in Patients With ITP

Immune Thrombocytopenia | Bruton Tyrosine Kinase

China
Sun Yat-sen University

Recruiting

A Phase II Study of Rituximab, Chidamide, Zanubrutinib-induced and CHOP Therapy

Double Express Diffuse Large B-cell Lymphoma

China
Ruijin Hospital

Active, not recruiting

Zanubrutinib, Lenalidomide and Rituximab (ZR2) in Elderly Treatment-naive Patients with Diffuse Large B-cell Lymphoma (DLBCL)

Diffuse Large B Cell Lymphoma

China
Qingdao Central Hospital

Recruiting

Efficacy and Safety of Rituximab Plus Zanubrutinib and Lenalidomide for Relapsed and Refractory Diffuse Large B Cell Lymphoma, a Multicenter, Open and Prospective Clinical Trial

Overall Survival

China
Peking Union Medical College Hospital

Recruiting

Zanuburutinib in Relapsed and Refractory iMCD: a Prospective, Single-center, Single-arm Trial (iMCD)

Idiopathic Multicentric Castleman's Disease

China
Ruijin Hospital

Recruiting

Zanubrutinib Combined With Tislelizumab in the Treatment of r/r PMBCL and EBV+ DLBCL

Primary Mediastinal Large B Cell Lymphoma | EBV-Positive DLBCL, Nos

China
The University of Hong Kong

Recruiting

Oral Dydrogesterone as Luteal Phase Support in Natural Cycle FET

Subfertility

China
Ruijin Hospital

Not yet recruiting

ARTA-based Chemo-free Bridging/Maintenance Therapy in CAR-T Treatment for High-Risk R/R B-NHL Ineligible for HDCT and ASCT

B-cell Non Hodgkin Lymphoma

China
Institute of Hematology & Blood Diseases Hospital...

Recruiting

Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WM (ZBR)

Waldenstrom Macroglobulinemia

China
LanZhou University
Beigene (Beijing) Biotechnology Co., Ltd

Not yet recruiting

Zanubrutinib in Maintenance Therapy of DLBCL Patients With Initial Remission

Diffuse Large B-cell Lymphoma (DLBCL)

China
Ruijin Hospital

Not yet recruiting

Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR) in High-risk Treatment-naive Patients with Follicular Lymphoma (FL)

Follicular Lymphoma

China
Shandong Provincial Hospital

Recruiting

Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma

Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | B-cell Non Hodgkin Lymphoma | High Grade B-Cell Lymphoma, Not Otherwise Specified | High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements

China
BeiGene

Completed

Safety and Pharmacokinetics of Zanubrutinib (BGB-3111) in Healthy Subjects and Those With Impaired Liver Function

Hepatic Insufficiency & Healthy Subjects

United States
Peking University People's Hospital

Recruiting

Zanubrutinib Monotherapy in Relapsed/Refractory Central Nervous System Lymphoma

CNS Lymphoma

China
BeiGene

Completed

Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies

B-cell Malignancies

United States, Korea, Republic of, Australia, New Zealand, United Kingdom, Italy
AstraZeneca
CISCRP; eResearch Technology, Inc.; Fortrea; CALYX Inc.

Recruiting

Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure

Heart Failure | Chronic Lymphocytic Leukaemia

Spain, Italy, United Kingdom, United States, Czechia, Poland
Zhejiang Cancer Hospital

Recruiting

ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCL

Diffuse Large B Cell Lymphoma

China

1
2
3
4
›

3

Subscribe